In a research note published August 8, Janney Capital analyst Kimberly Lee reiterated a Buy rating on Amicus Therapeutics (FOLD) with a $5 …
In a research report released yesterday, Janney Capital analyst Kimberly Lee reiterated a Buy rating on NPS Pharmaceuticals (NPSP) with a $37 fair …
In a research report issued Friday, Janney Capital analyst Kimberly Lee reiterated a Buy rating on Medivation Inc. (MDVN) with a $110 fair value estimate, following Medivation’s partner Astellas (ALPMY) second quarter results …
In a research report issued yesterday, Janney Capital Markets analyst Kimberly Lee reiterated a Buy rating on Vertex Pharmaceuticals Inc. (VRTX) and gave it a Fair Value Estimate …
In a research report released yesterday, Janney Capital analyst Kimberly Lee reiterated a Buy rating on Aegerion Pharmaceuticals (AEGR) on the heels of …
In a research report issued today, Janney Capital analyst Kimberly Lee reiterated a Sell rating on Sarepta Therapeutics (SRPT) with a $13 fair value, following today’s news of the termination of …
In a research note released this morning, Janney Capital analyst Kimberly Lee maintained a Buy rating on Raptor Pharmaceutical (RPTP) with a $17 …
In a research report published today, Janney Capital analyst Kimberly Lee maintained a Buy rating on Vertex Pharmaceuticals (VRTX) with a $110 price …
In a research note released today, Janney Capital analyst Kimberly Lee maintained a Neutral rating on PDL Biopharma (PDLI) with a $8 price target, ahead of the upcoming …
In a research note released this morning, Janney Capital analyst Kimberly Lee maintained a Buy rating on NPS Pharmaceuticals, Inc (NPSP) with a …
